AriBio Co., Ltd. is a South Korean biotechnology company headquartered in Seoul, South Korea, dedicated to developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2015, AriBio focuses on innovative approaches targeting protein aggregation and neuroprotection[1].
The company has advanced its lead candidate AR1001 through clinical development and is building a pipeline of next-generation therapies for Alzheimer's disease.
| Program | Target/Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| AR1001 | PDE5 inhibitor | Alzheimer's disease | Phase 2/3 | Active |
| AR1002 | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research |
| AR1003 | Anti-amyloid antibody | Alzheimer's disease | Discovery | Research |
AR1001 is a phosphodiesterase 5 (PDE5) inhibitor being developed for Alzheimer's disease. PDE5 inhibition is believed to provide neuroprotective effects through multiple pathways[2]:
Phase 2/3 Trial (2024-2025):
Phase 1 Studies:
The PDE5 target in Alzheimer's disease is supported by multiple lines of evidence:
AR1002 targets tau protein aggregation, a key pathological feature of Alzheimer's disease. This program is in preclinical development[3].
Mechanism:
Status:
AriBio's approach to Alzheimer's disease addresses multiple pathological hallmarks:
AriBio maintains collaborations with:
Headquarters: Seoul, South Korea
Founded: 2015
Leadership:
Funding:
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| Eli Lilly | Donanemab | Anti-Aβ mAb | Approved |
| Biogen/Eisai | Lecanemab | Anti-Aβ mAb | Approved |
| Cassava Sciences | Simufilam | Filamin A mod | Phase 3 |
| Roche | Gantenerumab | Anti-Aβ mAb | Phase 3 |
| AriBio | AR1001 | PDE5 inhibitor | Phase 2/3 |